HC Wainwright Brokers Increase Earnings Estimates for DMAC

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) – Stock analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for shares of DiaMedica Therapeutics in a research note issued on Wednesday, April 1st. HC Wainwright analyst M. Caufield now forecasts that the company will post earnings of ($0.17) per share for the quarter, up from their previous estimate of ($0.18). The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.19) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.75) EPS and FY2028 earnings at ($0.35) EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Monday, March 30th. The company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). The firm had revenue of ($0.03) million during the quarter, compared to analyst estimates of $13.50 million.

Several other research analysts have also issued reports on DMAC. Lake Street Capital reissued a “buy” rating on shares of DiaMedica Therapeutics in a research report on Monday, January 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Price Performance

DMAC stock opened at $6.48 on Friday. The company’s 50 day simple moving average is $7.76 and its 200-day simple moving average is $7.64. DiaMedica Therapeutics has a 52-week low of $3.19 and a 52-week high of $10.42. The firm has a market capitalization of $349.16 million, a P/E ratio of -9.26 and a beta of 1.16.

Institutional Investors Weigh In On DiaMedica Therapeutics

Large investors have recently made changes to their positions in the company. World Investment Advisors increased its position in shares of DiaMedica Therapeutics by 7.7% during the 4th quarter. World Investment Advisors now owns 36,975 shares of the company’s stock worth $294,000 after purchasing an additional 2,650 shares in the last quarter. Invesco Ltd. boosted its position in DiaMedica Therapeutics by 29.9% in the fourth quarter. Invesco Ltd. now owns 18,628 shares of the company’s stock valued at $148,000 after buying an additional 4,293 shares in the last quarter. XTX Topco Ltd acquired a new position in DiaMedica Therapeutics in the fourth quarter valued at about $234,000. Wellington Management Group LLP bought a new stake in DiaMedica Therapeutics during the fourth quarter worth about $825,000. Finally, Quadrature Capital Ltd bought a new stake in DiaMedica Therapeutics during the fourth quarter worth about $188,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics News Summary

Here are the key news stories impacting DiaMedica Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its Q1 2026 EPS forecast to ($0.17) from ($0.18), signaling slightly smaller expected losses for the quarter. MarketBeat Report
• Positive Sentiment: Q2 2026 EPS estimate was lifted to ($0.18) from ($0.19), another incremental improvement to near‑term profitability expectations. MarketBeat Report
• Positive Sentiment: Q3 2026 EPS now projected at ($0.19), up from ($0.20), continuing the trend of reduced loss estimates across 2026 quarters. MarketBeat Report
• Positive Sentiment: Q4 2026 EPS was raised to ($0.21) from ($0.22), consistent with HC Wainwright nudging 2026 quarterly forecasts toward smaller losses. MarketBeat Report
• Positive Sentiment: HC Wainwright lifted FY2026 and FY2027 EPS estimates to ($0.75) from ($0.79), trimming expected full‑year losses and implying improving operating outlook vs. prior forecasts. MarketBeat Report
• Positive Sentiment: FY2028 EPS was nudged to ($0.35) from ($0.37), another minor upgrade in the multi‑year outlook. MarketBeat Report
• Positive Sentiment: HC Wainwright published a long‑range estimate projecting FY2030 EPS of $0.56, marking an expected transition to profitability in their model — a materially positive long‑term signal if the company hits the pathway to that outcome. MarketBeat Report
• Negative Sentiment: HC Wainwright slightly lowered its FY2029 EPS view to $0.14 from $0.15 — a small downgrade that partially offsets the otherwise uniform set of upgrades. MarketBeat Report

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.